Search
mRNA-1010
go.drugbank.com/drugs/DB22484Approved[L64058] Each dose contains three mRNAs encapsulated in lipid nanoparticles, each encoding the hemagglutinin (HA) glycoprotein of one influenza strain recommended for the season; after intramuscular injection
Berdazimer
go.drugbank.com/drugs/DB18712ApprovedIt is one of the 5 most prevalent skin diseases in the world and the third-most common viral skin infection in children.
Sulfacytine
go.drugbank.com/drugs/DB01298ApprovedBacterial sensitivity is the same for the various sulfonamides, and resistance to one sulfonamide indicates resistance to all. Most sulfonamides are readily absorbed orally.
Azvudine
go.drugbank.com/drugs/DB16407InvestigationalAzvudine is under investigation in clinical trial NCT04668235 (Study on Safety and Clinical Efficacy of AZVUDINE in COVID-19 Patients (Sars-cov-2 Infected)).
VB10.16
go.drugbank.com/drugs/DB17512InvestigationalIt is composed of three parts, one encodes the E6/E7 fusion protein of human papillomavirus (HPV) type 16 (HPV16), a dimerization entity, and the part encoding a protein that specifically binds to antigen-presenting
ATX-201
go.drugbank.com/drugs/DB05765InvestigationalATX-201 is one of a family of novel compounds that inhibits microtubule polymerization. It is developed by Kythera Biopharmaceuticals, Inc. for the treatment of actinic keratosis.
1alpha,24S-Dihydroxyvitamin D2
go.drugbank.com/drugs/DB06117ExperimentalLR-103 is one of the D-hormones produced from Hectorol. It is developed for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease (CKD).
BNT162a1 SARS-CoV-2 Vaccine
go.drugbank.com/drugs/DB15697ExperimentalBNT162a1 is one of four advanced mRNA-based vaccines being developed through "Project Lightspeed," a joint program between Pfizer and BioNTech.
BNT162c2 SARS-CoV-2 Vaccine
go.drugbank.com/drugs/DB15698ExperimentalBNT162c2 is one of four advanced mRNA-based vaccines being developed through "Project Lightspeed," a joint program between Pfizer and BioNTech.
FM-VP4
go.drugbank.com/drugs/DB05449InvestigationalFM-VP4, is a novel hydrophilic phytostanol analogue representing a new class in cholesterol-lowering drugs called cholesterol absorption inhibitors. FM-VP4 has been shown to inhibit cholesterol absorption and to lower plasma LDL-choleste...